StemCyte has now supplied more than 800 transplants
StemCyte was founded in 1997 by Dr. Robert Chow to focus exclusively on developing industry-leading UCB processing technologies and establishing the largest, most racially diverse, and highest quality public bank of UCB stem cell products in the industry. In 2000, Dr. Chow established the StemCyte laboratory in Arcadia, CA and in Taiwan. Both the U.S. and Taiwan public banks and laboratories became operational in 2001. By the end of 2002, StemCyte's team had established one of the largest, most racially diverse, and highest quality UCB stem cell banks in the world.


After years of previous experience at UCLA, Dr. Chow invented a number of proprietary processes, all designed to ensure that the least number of stem cells would be lost or killed post-processing and post-thaw. Studies have shown that successful patient engraftment and patient survival outcome is directly correlated to the number of stem cells provided. The base of the Company's proprietary processing strategy is a commitment to plasma depletion without red cell reduction processing, which is contrary to other cord blood banks that have turned to a red cell reduction process. After developing these methods and then institutionalizing them into over 400 standard operating procedures, the Company then demonstrated initial transplant success and began to establish a reputation and basis of trust among leading transplant centers around the world. Today, the Company has supplied more than 900 cord blood units for transplant to over 150 leading worldwide transplant centers within over 25 countries on 6 continents.


To date, more than 70 diseases have been successfully treated with stem cells. These include cancers (leukemias, lymphomas, myelomas), blood disorders (thalassemias, sickle cell anemia, Fanconi anemia), and immune deficiency diseases.
StemCyte has supplied more than 900 cord blood units for transplant worldwide. To see the locations of our transplant units, click on the map above.